Measurement of Circulating Cell-Free DNA Levels by a New Simple Fluorescent Test in Patients With Primary Colorectal Cancer

Czeiger, David; Shaked, Gad; Eini, Hadar; Vered, Ilan; Belochitski, Olga; Avriel, Avital; Ariad, Samuel; Douvdevani, Amos

doi:10.1309/ajcp4rk2ihvkttzv

Cited by 68 publications

(66 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In general, the levels are higher in mCRC patients than in healthy controls, as shown in Table 1 [15,20,47,58,[63][64][65][66][67][68][69][70][71][72]; and the levels have some correlation to stage as reported in a limited number of studies [15,41,68,73] in primary CRC. These findings give important biological information, and researchers suggest that cfDNA has potential as a diagnostic or screening tool; a potential that is currently being investigated by several groups.…”

Section: Methodsmentioning

confidence: 71%

“…It is therefore relevant to analyze the relation between cfDNA and CEA. As illustrated from the summary in Table 2, there is considerable variation in the measures, methods and parameter used to compare or combine the information from CEA and cfDNA analysis [15,20,32,33,39,41,[65][66][67][68][69][70][71][72][81][82][83]. The table includes studies identified by a systematic literature search of circulating DNA in CRC (all stages) as illustrated by Supplementary Figure 1.…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Methodological, biological and clinical aspects of circulating free DNA in metastatic colorectal cancer

Spindler

2016

Acta Oncologica

View full text Add to dashboard Cite

Background: Circulating DNA can be used to measure the total cell-free DNA (cfDNA) and for detection and quantification of tumor-specific genetic alterations in the peripheral blood, and the broad clinical potential of circulating DNA has attracted increasing focus over the past decade. Concentrations of circulating DNA are high in metastatic colorectal cancer (CRC), and the total levels of cfDNA have been reported to hold strong prognostic value. Colorectal tumors are characterized by a high frequency of well known, clinically relevant genetic alteration, which is readily detected in the cfDNA and holds potential for tailoring of palliative therapy and for monitoring during treatment. This review aims to present the current literature which has specifically reported data on the potential utility of cfDNA and on tumor-specific mutations in metastatic colorectal cancer (mCRC). Method: Methodological, biological and clinical aspects are discussed based on the most recent development in this specific setting, and eligible studies were identified by systematic literature searched from Pubmed and EMBASE in addition to conference papers and communications. Results: The literature regarding cfDNA in CRC is broad and heterogeneous concerning aims, nomenclature, methods, cohorts and clinical endpoints and consequently difficult to include in a single systematic search. However, the available data underline a strong clinical value of measuring both total cfDNA levels and tumor-specific mutations in the plasma of patients with mCRC, pre-and during systemic therapy. Conclusion: This paper had gathered the most recent literature on several aspects of cfDNA in mCRC, including methodological, biological and clinical aspects, and discussed the large clinical potential in this specific setting, which needs to be validated in carefully designed prospective studies in statistically relevant cohorts.

show abstract

Section: Methodsmentioning

confidence: 71%

Section: Methodsmentioning

confidence: 99%

Methodological, biological and clinical aspects of circulating free DNA in metastatic colorectal cancer

Spindler

2016

Acta Oncologica

View full text Add to dashboard Cite

show abstract

“…On the other hand, during necrosis, apoptosis, autophagy and mitochondrial catastrophe, the tumour cells release DNA fragments of different sizes, which leads to raised levels of circulating cell-free DNA with longer fragments in serum or plasma 21. These studies have shown the existence of elevated levels of circulating cell-free DNA, probably released from cancer cells into the plasma or serum, which occurs in several types of cancer, such as lung,13 14 22 23 renal,9 prostate,28 29 breast,16 19 21 26 27 and CRC 15 18 20 25…”

Section: Introductionmentioning

confidence: 99%

Circulating cell-free DNA in serum as a biomarker of colorectal cancer

et al. 2013

View full text Add to dashboard Cite

show abstract

“…This is the fourth study based on our innovative and simple technique to measure CFD levels in cancer patients [17][18][19]. Various complex techniques have been used to evaluate CFD concentrations, fragmentation, mutations, and epigenetic changes in cancer patients, including RCC.…”

Section: Discussionmentioning

confidence: 99%

Circulating Cell-Free DNA Levels in Patients with Metastatic Renal Cell Carcinoma

et al. 2017

Self Cite

View full text Add to dashboard Cite

Background: Limited data about biomarkers are available to predict the outcomes of targeted therapy in metastatic renal cell carcinoma (mRCC). Circulating cell-free DNA (CFD) is elevated in various cancers. Patients and Methods: We performed a prospective study of patients with mRCC who received targeted therapy in the Soroka Medical Center between 2013 and 2015. CFD levels were measured using a simple fluorometric assay. Blood samples for CFD were collected before treatment and at weeks 1, 4, 12, 18, and 24 of treatment. The normal cut-off level of CFD was defined as 800 ng/ml. The association of CFD with objective response, progression-free survival (PFS), and overall survival was tested, with adjustment for known confounding risk factors. Results: A total of 23 patients were included; 18 were treated with first-line therapy and 5 with second- and third-line therapies. Patients with normal pretreatment CFD level had a better PFS versus patients with increased levels (p = 0.023). In multivariate analysis, factors associated with PFS were pretreatment CFD levels (p = 0.020) and Heng risk (p = 0.006). Conclusions: Elevated pretreatment CFD levels measured using a simple fluorometric assay may be associated with a worse PFS in patients with mRCC. A larger prospective study is warranted in order to validate our observation.

show abstract

Measurement of Circulating Cell-Free DNA Levels by a New Simple Fluorescent Test in Patients With Primary Colorectal Cancer

Cited by 68 publications

References 14 publications

Methodological, biological and clinical aspects of circulating free DNA in metastatic colorectal cancer

Methodological, biological and clinical aspects of circulating free DNA in metastatic colorectal cancer

Circulating cell-free DNA in serum as a biomarker of colorectal cancer

Circulating Cell-Free DNA Levels in Patients with Metastatic Renal Cell Carcinoma

Contact Info

Product

Resources

About